Answers are grounded in this paper and cite their sources.
// Duan Feng 1 , Xie Hui 2 , Lu Shi-Chun 3 , Bai Yan-Hua 1 , Cui Li 1 , Li Xiao-Hui 1 and Yan Jie-Yu 1 1 Department of Interventional Radiology, The General Hospital of Chinese People’s Liberation Army, Beijing, China 2 Department of Interventional Therapy, 302 Hospital of Chinese People’s Liberation Army, Beijing, China 3 Department of Hepatobiliary Surgery, The General Hospital of Chinese People’s Liberation Army, Beijing, China Correspondence to: Duan Feng, email: // Keywords : hepatocellular carcinoma, nivolumab, anti-PD1, immunotherapy, Immunology and Microbiology Section, Immune response, Immunity Received : June 05, 2017 Accepted : July 13, 2017 Published : August 08, 2017 Abstract Purpose: To evaluate efficacy and safety of anti-PD1 therapy with nivolumab for treatment of advanced hepatocellular carcinoma (HCC). Methods: From Jan 2016 to Jan 2017, eleven cases of HCC (average age of 51.8-year), 4 at stage B and 7 at stage C, according to Barcelona Clinic Liver Cancer staging, were treated with nivolumab. There were 4 patients with lung metastasis, 1 with portal vein tumor thrombus, 1 with abdominal metastasis and 1 with bone metastasis. The protocol was nivolumab, 3 mg/kg, on day 1, q3w. All patients were treated for more than 4 cycles. During anti-PD1 treatment period, 6 patients also received sorafenib and 1 patient received cytokine-induced killer cell therapy. Objective response and clinical adverse events were evaluated retrospectively. Results: Patients underwent a total of 80 cycles of nivolumab therapy, ranging between 4 and 18 cycles per patient. Nivolumab was associated with a disease control rate of 81.8%, with an objective response of 63.6% (Modified Response Evaluation Criteria in Solid Tumors). No adverse effects related to nivolumab were noted. Conclusion: Our experience shows that nivolumab could achieve acceptable outcome in HCC patients and may serve as an optional treatment, especially for patients who failed to gain a benefit from routine treatments.
No takes yet. Share an insight, caveat, or question.
Duan et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: